Investing in Transformational Therapeutics
View PortfolioWorking with Frazier when times were tough in a prior company gave me insight into their character and high integrity. Not only are they smart, low ego and not afraid to think big, they genuinely care about supporting their CEOs and companies.
Angie You
CEO
The Frazier team really distinguish themselves by being true partners to their companies. They have supported us every step of the way with resources, guidance and expertise as we built the company.
Frank Watanabe
Founder & CEO
Frazier has been a long-standing partner to Krystal since our IPO in 2017. They are a firm of intellect and integrity, and I truly value their support as we evolved from an idea into a fully integrated biotechnology company.
Krish Krishnan
Chairman & CEO
I thoroughly enjoy working with the Frazier team both as investors and as a critical sounding board for new ideas. They are approachable and responsive and bring a well-informed, balanced view of opportunities and risks. Frazier partners particularly well with management teams by taking a patient and pragmatic view of the path to value creation.
Stephen Dilly
CEO
Who We Are
Frazier Life Sciences is a healthcare investment firm focusing on companies developing novel therapeutics. We have two core funds that enable investments across all stages of therapeutics companies:
Venture Funds
Our Venture Funds primarily invest in private companies, focusing on company creation (over 30 companies formed since 2005) and Series A & B companies. We form true partnerships with distinctive entrepreneurs to build highly valuable companies and accelerate advancement of new therapeutic options for patients. Our latest Venture Fund is Frazier Life Sciences XI, a $987 million fund that was raised in 2022.
Public Funds
Our Public Funds provide capital to small- and mid-cap public biotech companies in financings, including follow-ons including CMPOs, PIPEs, IPOs, as well as supporting our companies in the open market. We partner with our public portfolio companies much as we do with our private portfolio companies. The Public Funds are investing over $1 billion of committed capital.
Newsroom
View All
Frazier Life Sciences Appoints John Smither and Jim Williams as Senior…
Frazier Life Sciences Appoints John Smither and Jim Williams as Senior…
link
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
link
MBX Biosciences Announces Pricing of Initial Public Offering
MBX Biosciences Announces Pricing of Initial Public Offering
link
Scorpion Therapeutics Announces $150 Million Series C Financing to…
Scorpion Therapeutics Announces $150 Million Series C Financing to Advance…
linkDrug Approvals
Our goal is to invest in therapeutics that ultimately benefit patients, and our portfolio has generated over 40 FDA approved therapeutics since 2010. Examples include:
Krystal Biotech
Acerta Pharma
Arcutis Biotherapeutics
Mirum Pharmaceuticals
Phathom Pharmaceuticals
AnaptysBio
Ignyta
Entasis Therapeutics
Silvergate Pharmaceuticals
Calistoga Pharmaceuticals
Certain statements about Frazier Life Sciences made by portfolio company executives herein are intended to illustrate the work of Frazier’s team with such portfolio companies. Portfolio company executives were not compensated in connection with their participation, although they generally receive compensation and investment opportunities in connection with their portfolio company roles, and in certain cases are also owners of portfolio company securities, Senior Advisors, and/or investors in Frazier-sponsored vehicles. Such compensation and investments subject participants to potential conflicts of interest in making the statements herein.
